Next-Generation Immunotherapy: Combining Virus-Specific T Cells with Other Immuno-Oncology Technologies to Treat Solid Tumors
Dr. John Connolly, CSO of Tessa Therapeutics, reveals how a new approach to cell-based therapy in cancer could circumvent severe immunotherapy side effects and effectively target aggressive solid tumors